Overcoming translational barriers in H3K27-altered diffuse midline glioma: Increasing the drug-tumor residence time.
Erica A PowerJulian S RechbergerLiang ZhangJu-Hee OhJacob B AndersonCody L NesvickJizhi GeEdward H HinchcliffeWilliam F ElmquistDavid J DanielsPublished in: Neuro-oncology advances (2023)
These studies provide evidence for increasing drug-tumor residence time of promising targeted therapies via extended CED as a valuable treatment strategy for DMG.